secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062046
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Q3 net loss $16.7M; epetraborole Phase 3 enrollment underway
-----------------------------------------------------------------------------

- Net loss $16.7M for Q3 2023, up from $11.3M in Q3 2022; R&D and G&A expenses increased.
- Cash and investments $150.2M at Sept 30; $70M raised in August stock offering; cash runway through summer 2025.
- Phase 3 part of pivotal epetraborole trial in refractory MAC lung disease initiated; Phase 2 top-line data expected summer 2024.
- Received Bill & Melinda Gates Foundation grant for TB/malaria; exclusive license for Chagas disease candidate AN2-502998.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/0000950170-23-062046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/antx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer